Refine
Document Type
- Article (23)
Has Fulltext
- yes (23)
Is part of the Bibliography
- no (23)
Keywords
- Ataxia-telangiectasia (1)
- CVID (1)
- Crystal Structure (1)
- European Society for Immunodeficiencies (ESID) (1)
- German PID-NET registry (1)
- High Pressure Stability (1)
- IR (1)
- IgA deficiency (1)
- IgG substitution therapy (1)
- Immunodeficiency (1)
Institute
- Biochemie und Chemie (20)
- Medizin (2)
- Biochemie, Chemie und Pharmazie (1)
- Geowissenschaften (1)
Introduction: The German PID-NET registry was founded in 2009, serving as the first national registry of patients with primary immunodeficiencies (PID) in Germany. It is part of the European Society for Immunodeficiencies (ESID) registry. The primary purpose of the registry is to gather data on the epidemiology, diagnostic delay, diagnosis, and treatment of PIDs.
Methods: Clinical and laboratory data was collected from 2,453 patients from 36 German PID centres in an online registry. Data was analysed with the software Stata® and Excel.
Results: The minimum prevalence of PID in Germany is 2.72 per 100,000 inhabitants. Among patients aged 1–25, there was a clear predominance of males. The median age of living patients ranged between 7 and 40 years, depending on the respective PID. Predominantly antibody disorders were the most prevalent group with 57% of all 2,453 PID patients (including 728 CVID patients). A gene defect was identified in 36% of patients. Familial cases were observed in 21% of patients. The age of onset for presenting symptoms ranged from birth to late adulthood (range 0–88 years). Presenting symptoms comprised infections (74%) and immune dysregulation (22%). Ninety-three patients were diagnosed without prior clinical symptoms. Regarding the general and clinical diagnostic delay, no PID had undergone a slight decrease within the last decade. However, both, SCID and hyper IgE- syndrome showed a substantial improvement in shortening the time between onset of symptoms and genetic diagnosis. Regarding treatment, 49% of all patients received immunoglobulin G (IgG) substitution (70%—subcutaneous; 29%—intravenous; 1%—unknown). Three-hundred patients underwent at least one hematopoietic stem cell transplantation (HSCT). Five patients had gene therapy.
Conclusion: The German PID-NET registry is a precious tool for physicians, researchers, the pharmaceutical industry, politicians, and ultimately the patients, for whom the outcomes will eventually lead to a more timely diagnosis and better treatment.
Several oxoplatinates (IV) and -rhenates (VII) with isolated PtO6 or ReO6 octahedra respectively surrounded by lithium, sodium, magnesium, calcium, strontium and barium atoms were prepared. From infrared spectra (KBr pellet technique) force constants were calculated. The values varied. depending on an inductive field effect caused by the alcaline and alcaline earth atoms, which increased in the following order: Ba<Sr<Ca ≈ ≪ Mg. By means of bond order it can be predicted that for central atoms with d0 or d10 configuration and with an oxidation state lower than six only such hexaoxometallates will be formed in which the alcaline or alcaline earth atoms intensity the force constant by a strong inductive effect. PtO6 requires an additional force which lowers the symmetry of PtO6 and stabilizes the hexaoxoplatinates (IV).
Patients with ataxia-telangiectasia (A-T) suffer from progressive cerebellar ataxia, immunodeficiency, respiratory failure, and cancer susceptibility. From a clinical point of view, A-T patients with IgA deficiency show more symptoms and may have a poorer prognosis. In this study, we analyzed mortality and immunity data of 659 A-T patients with regard to IgA deficiency collected from the European Society for Immunodeficiencies (ESID) registry and from 66 patients with classical A-T who attended at the Frankfurt Goethe-University between 2012 and 2018. We studied peripheral B- and T-cell subsets and T-cell repertoire of the Frankfurt cohort and survival rates of all A-T patients in the ESID registry. Patients with A-T have significant alterations in their lymphocyte phenotypes. All subsets (CD3, CD4, CD8, CD19, CD4/CD45RA, and CD8/CD45RA) were significantly diminished compared to standard values. Patients with IgA deficiency (n = 35) had significantly lower lymphocyte counts compared to A-T patients without IgA deficiency (n = 31) due to a further decrease of naïve CD4 T-cells, central memory CD4 cells, and regulatory T-cells. Although both patient groups showed affected TCR-ß repertoires compared to controls, no differences could be detected between patients with and without IgA deficiency. Overall survival of patients with IgA deficiency was significantly diminished. For the first time, our data show that patients with IgA deficiency have significantly lower lymphocyte counts and subsets, which are accompanied with reduced survival, compared to A-T patients without IgA deficiency. IgA, a simple surrogate marker, is indicating the poorest prognosis for classical A-T patients. Both non-interventional clinical trials were registered at clinicaltrials.gov 2012 (Susceptibility to infections in ataxia-telangiectasia; NCT02345135) and 2017 (Susceptibility to Infections, tumor risk and liver disease in patients with ataxia-telangiectasia; NCT03357978)
Über den Einfluß der Kationen auf die Kraftkonstanten der WO-Bindung in den Hexaoxowolframaten (VI)
(1970)
Über Lithiumhexaoxometallate
(1969)
Über Natriumhexaoxometallate
(1969)
Über Li6ReO6
(1969)
Li6UO6 has a reversible phase transformation at 680°C and decomposes above about 850°C. At high pressure the low temperature modification becomes unstable because of an invariant point in the system Li2O—Li4UO5 at approximately 13 Kb and 620°C. β-Li6UO6 has a triclinic unit cell with a = 5.203, b= 5.520, c = 5.536 Å, α = 114.7, β = 120.7 and γ = 75.5°. The close relationship between the crystal structures of Li6TeO6 and Li6UO6 is also suggested from similar infrared spectra and from partial solid solution Li6UO6—Li6TeO6.